PBPK-PD Topo1-Based ADC
Indication: Solid tumors (HER2-positive and Trop-2-positive cancers)
PBPK-PD model for topoisomerase I-targeting antibody-drug conjugates (Topo1 ADCs) including sacituzumab govitecan (Trodelvy, anti-Trop-2) and trastuzumab deruxtecan (Enhertu, anti-HER2). Simulates ADC disposition, linker cleavage, payload distribution, and tumor pharmacodynamics for camptothecin-based payloads (SN-38, DXd). Key for predicting efficacy and toxicity in breast, gastric, lung, and other solid tumors.
Drug Overview
Clinical Context
- Molecular Target
- Topoisomerase I
- Drug Class
- Antibody-Drug Conjugate
- Therapeutic Area
- Oncology
- Indication
- Solid tumors (HER2-positive and Trop-2-positive cancers)
- Route of Administration
- IV
Model Information
- Model Type
- PBPK-PD
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
About This Simulator
This interactive pharmacokinetic simulator for PBPK-PD Topo1-Based ADC allows you to explore concentration-time profiles under different dosing scenarios. The underlying PBPK-PD model characterizes the pharmacokinetics of this antibody-drug conjugate following iv administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration). The pharmacodynamic component links drug exposure to therapeutic or safety endpoints.
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the PBPK-PD Topo1-Based ADC PK simulator?
This is a free, interactive pharmacokinetic simulator for PBPK-PD Topo1-Based ADC used in Solid tumors (HER2-positive and Trop-2-positive cancers). It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does PBPK-PD Topo1-Based ADC belong to?
PBPK-PD Topo1-Based ADC is classified as a Antibody-Drug Conjugate that targets Topoisomerase I. It is used in the Oncology therapeutic area.
What route of administration does this model simulate?
This simulator models IV administration of PBPK-PD Topo1-Based ADC. The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a PBPK-PD model. PBPK models use physiological parameters to predict drug distribution across tissues and organs.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
Related Simulators
PopPK of Docetaxel
capecitabine
PBPK-PD of ADCs
Trodelvy PopPK
Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC), HR+/HER2-negative metastatic breast cancer after endocrine and CDK4/6 inhibitor therapy, and locally advanced or metastatic urothelial cancer; TROP2-directed ADC with SN-38 payload
Datroway PopPK
Locally advanced or metastatic non-squamous NSCLC (TROPION-Lung08), HR+/HER2-low/negative metastatic breast cancer (TROPION-Breast01), and triple-negative breast cancer; TROP2-directed ADC with DXd payload
Enhertu PopPK
HER2-positive breast cancer, gastric/gastroesophageal adenocarcinoma, NSCLC
Ready to Simulate?
Launch the PBPK-PD Topo1-Based ADC simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community